The Effects of Denosumab on the Pharmacokinetics of Etanercept in Postmenopausal Women With Low Mineral Density( BMD) and Rheumatoid Arthritis (RA)

Trial Profile

The Effects of Denosumab on the Pharmacokinetics of Etanercept in Postmenopausal Women With Low Mineral Density( BMD) and Rheumatoid Arthritis (RA)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Denosumab (Primary) ; Etanercept
  • Indications Postmenopausal osteoporosis; Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Sponsors Amgen
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 08 Mar 2016 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
    • 22 Sep 2015 Planned End Date changed from 1 Sep 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top